Mission GBM
Subscribe
Sign in
Home
Glossary of Terms
Brain Cancer News
Brain Cancer Science Talk
Clinical Trials
FAQs
Goals of Care
Investing in Brain Cancer
Julie's Journey
Meet the Team
Archive
About
Clinical Trials
Breaking News: FDA Approves Vorasidenib (Voranigo®)
A great day for Low Grade Astrocytoma and Oligodendroglioma Patients with IDH1/IDH2 Mutations
Aug 6
•
Scott L. Rakestraw, PhD
7
Share this post
Mission GBM
Breaking News: FDA Approves Vorasidenib (Voranigo®)
Copy link
Facebook
Email
Notes
More
Michael Lim, MD – Brain Cancer Science Talk (Episode 7)
Stanford’s Chair of Neurosurgery discusses the promise and challenges associated with immunotherapy for brain tumors
Jul 15
•
Scott L. Rakestraw, PhD
6
Share this post
Mission GBM
Michael Lim, MD – Brain Cancer Science Talk (Episode 7)
Copy link
Facebook
Email
Notes
More
30:07
The Reality of Clinical Trials – Part 2
Bess Stillman, MD details how the Regulatory process needs to be modernized to better serve both cancer patients and Sponsors. We extend the concepts to…
Jul 2
•
Scott L. Rakestraw, PhD
3
Share this post
Mission GBM
The Reality of Clinical Trials – Part 2
Copy link
Facebook
Email
Notes
More
The Reality of Clinical Trials - Part 1
Often a frustrating slog through inaccurate information and hidden conflicts of interest
Apr 10
•
Scott L. Rakestraw, PhD
4
Share this post
Mission GBM
The Reality of Clinical Trials - Part 1
Copy link
Facebook
Email
Notes
More
Marizomib Fails a Phase 3 Clinical Trial in ndGBM Patients
Big Study. Muddy Biology. Ugh!
Mar 29
•
Scott L. Rakestraw, PhD
1
Share this post
Mission GBM
Marizomib Fails a Phase 3 Clinical Trial in ndGBM Patients
Copy link
Facebook
Email
Notes
More
Novocure Reports METIS Top Line Clinical Trial Results for Brain Metastases from NSCLC
Promising, but we will wait for the full data presentation
Mar 27
•
Scott L. Rakestraw, PhD
2
Share this post
Mission GBM
Novocure Reports METIS Top Line Clinical Trial Results for Brain Metastases from NSCLC
Copy link
Facebook
Email
Notes
More
Breakthrough Results from the INDIGO Trial of Vorasidenib in Low Grade Glioma (LGG)
Great news for IDH-mutant LGG patients…and an object lesson in investable theses for brain cancer
Jun 7, 2023
•
Scott L. Rakestraw, PhD
5
Share this post
Mission GBM
Breakthrough Results from the INDIGO Trial of Vorasidenib in Low Grade Glioma (LGG)
Copy link
Facebook
Email
Notes
More
Day One Biopharmaceuticals Announces Top Line Data for the FIREFLY-1 Pivotal Phase 2 Trial in Pediatric Low Grade Glioma
Meaningful clinical responses to tovorafenib suggest an important new tool in the Brain Cancer Toolbox
Jan 12, 2023
•
Scott L. Rakestraw, PhD
2
Share this post
Mission GBM
Day One Biopharmaceuticals Announces Top Line Data for the FIREFLY-1 Pivotal Phase 2 Trial in Pediatric Low Grade Glioma
Copy link
Facebook
Email
Notes
More
Big News: Moderna and Merck Report Phase 2b Data for an mRNA Cancer Vaccine + Pembrolizumab
Further Evidence that the Central Hypothesis is gaining traction in cancer immunotherapy
Dec 14, 2022
•
Scott L. Rakestraw, PhD
5
Share this post
Mission GBM
Big News: Moderna and Merck Report Phase 2b Data for an mRNA Cancer Vaccine + Pembrolizumab
Copy link
Facebook
Email
Notes
More
SNO Storm: Phase 3 Results for DCVax-L
Highlights from the Society for Neuro-Oncology (SNO) 2022 Annual Meeting
Nov 18, 2022
•
Scott L. Rakestraw, PhD
5
Share this post
Mission GBM
SNO Storm: Phase 3 Results for DCVax-L
Copy link
Facebook
Email
Notes
More
Share
Copy link
Facebook
Email
Notes
More
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
